TransForm Pharmaceuticals Inc has entered into a deal with Abbott Laboratories to apply TransForm's technologies to enhance certain investigational and marketed product development programmes, according to a company release.

Under the collaboration, TransForm's scientists will conduct comprehensive crystallization and formulation studies of selected Abbott compounds.

"This may result in treatment options that provide enhanced efficacy, tolerability, dosing and convenience for patients," said Fritz Richter, divisional vice president, Global Preclinical Drug Development, Abbott Laboratories.

Although work will start immediately, financial terms were not disclosed.